HIGHLIGHTS
- who: Chenghai Zhang from the of Education), Department of Gastrointestinal Surgery IV, Peking University Beijing, China have published the article: The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study, in the Journal: (JOURNAL)
- what: A total of 87 cases were excluded from the study for various reasons (Fig 1). This study demonstrated that the proportion of downstaging rate was higher in the PTXS group (38.5%) than that in the SOX group (29.9%), although there was no . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.